[1]
Margolis DJ, Lewis VL. A literature assessment of the use of miscellaneous topical agents, growth factors, and skin equivalents for the treatment of pressure ulcers. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]. 1995 Feb:21(2):145-8
[PubMed PMID: 7894932]
[2]
Chan A, Ignoffo RJ. Survey of topical oral solutions for the treatment of chemo-induced oral mucositis. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 2005 Dec:11(4):139-43
[PubMed PMID: 16595065]
Level 3 (low-level) evidence
[3]
He P, Zou Y, Hu Z. Advances in aluminum hydroxide-based adjuvant research and its mechanism. Human vaccines & immunotherapeutics. 2015:11(2):477-88. doi: 10.1080/21645515.2014.1004026. Epub
[PubMed PMID: 25692535]
Level 3 (low-level) evidence
[4]
Becker LC, Boyer I, Bergfeld WF, Belsito DV, Hill RA, Klaassen CD, Liebler DC, Marks JG Jr, Shank RC, Slaga TJ, Snyder PW, Andersen FA. Safety Assessment of Alumina and Aluminum Hydroxide as Used in Cosmetics. International journal of toxicology. 2016 Nov:35(3 suppl):16S-33S
[PubMed PMID: 27913785]
[5]
Willhite CC, Karyakina NA, Yokel RA, Yenugadhati N, Wisniewski TM, Arnold IM, Momoli F, Krewski D. Systematic review of potential health risks posed by pharmaceutical, occupational and consumer exposures to metallic and nanoscale aluminum, aluminum oxides, aluminum hydroxide and its soluble salts. Critical reviews in toxicology. 2014 Oct:44 Suppl 4(Suppl 4):1-80. doi: 10.3109/10408444.2014.934439. Epub
[PubMed PMID: 25233067]
Level 1 (high-level) evidence
[6]
Hogenesch H. Mechanism of immunopotentiation and safety of aluminum adjuvants. Frontiers in immunology. 2012:3():406. doi: 10.3389/fimmu.2012.00406. Epub 2013 Jan 10
[PubMed PMID: 23335921]
[7]
Krewski D, Yokel RA, Nieboer E, Borchelt D, Cohen J, Harry J, Kacew S, Lindsay J, Mahfouz AM, Rondeau V. Human health risk assessment for aluminium, aluminium oxide, and aluminium hydroxide. Journal of toxicology and environmental health. Part B, Critical reviews. 2007:10 Suppl 1(Suppl 1):1-269
[PubMed PMID: 18085482]
[8]
Golper TA, Hartstein AI, Morthland VH, Christensen JM. Effects of antacids and dialysate dwell times on multiple-dose pharmacokinetics of oral ciprofloxacin in patients on continuous ambulatory peritoneal dialysis. Antimicrobial agents and chemotherapy. 1987 Nov:31(11):1787-90
[PubMed PMID: 3435126]
[9]
Frost RW, Lasseter KC, Noe AJ, Shamblen EC, Lettieri JT. Effects of aluminum hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin. Antimicrobial agents and chemotherapy. 1992 Apr:36(4):830-2
[PubMed PMID: 1503446]
[10]
Arayne MS, Sultana N, Hussain F. Interactions between ciprofloxacin and antacids--dissolution and adsorption studies. Drug metabolism and drug interactions. 2005:21(2):117-29
[PubMed PMID: 16355977]
[11]
Krishna R, East L, Larson P, Valiathan C, Butterfield K, Teng Y, Hernandez-Illas M. Effect of metal-cation antacids on the pharmacokinetics of 1200 mg raltegravir. The Journal of pharmacy and pharmacology. 2016 Nov:68(11):1359-1365. doi: 10.1111/jphp.12632. Epub 2016 Sep 27
[PubMed PMID: 27671833]
[12]
Becker C, Frey R, Unger S, Artmeier-Brandt U, Weimann G, Mück W. Effects of omeprazole and aluminum hydroxide/magnesium hydroxide on riociguat absorption. Pulmonary circulation. 2016 Mar:6(Suppl 1):S43-8. doi: 10.1086/682228. Epub
[PubMed PMID: 27162626]